NCI Budget Will Increase, But How Much?

The fiscal year 2003 budget request for the National Cancer Institute is a record $4.72 billion, a $510 million, or 12%, increase over the present appropriation. But this "president's budget," submitted to Congress in February, falls $970 million short of NCI's own "bypass budget" request, which seeks $5.69 billion, a breath-taking increase of $1.48 billion, 35%, over the present appropriation, and a whopping $1.51 billion more than President George W. Bush requested for it last year. The bypas

Written byTed Agres
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The bypass budget is so-called because, under the National Cancer Act of 1971, NCI's budget request is submitted directly to the president, bypassing reviews by the National Institutes of Health and the Department of Health and Human Services. In recent years, Congress has awarded NCI more than the president requested but less than the institute has sought.

At $4.72 billion, the president's budget request for NCI is the largest among all the NIH institutes and centers. In contrast, government support for cancer research in Great Britain last year totaled about £160 million, according to the Medical Research Council.

The NIH institutes and centers, including NCI, are expected to benefit from the positive momentum in Congress to complete the doubling of NIH's budget, requested at $23.3 billion for next year. Nevertheless, the NCI request falls short of Bush's goal to increase the cancer institute's budget to $5.1 billion by fiscal 2003.1 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies